Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

T Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.

Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance R, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM.

Clin Cancer Res. 2019 Sep 26. pii: clincanres.3199.2018. doi: 10.1158/1078-0432.CCR-18-3199. [Epub ahead of print]

PMID:
31558475
2.

Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes.

Smith CC, Chai S, Washington AR, Lee SJ, Landoni E, Field K, Garness J, Bixby LM, Selitsky SR, Parker JS, Savoldo B, Serody JS, Vincent BG.

Cancer Immunol Res. 2019 Oct;7(10):1591-1604. doi: 10.1158/2326-6066.CIR-19-0155. Epub 2019 Sep 12.

PMID:
31515258
3.

NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma.

Xu X, Huang W, Heczey A, Liu D, Guo L, Wood MS, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, Savoldo B, Dotti G, Metelitsa LS.

Clin Cancer Res. 2019 Sep 4. pii: clincanres.0421.2019. doi: 10.1158/1078-0432.CCR-19-0421. [Epub ahead of print]

PMID:
31484667
4.

In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.

Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, Landoni E, Du H, Savoldo B, Ferrone S, Dotti G, Sconocchia G.

Int J Cancer. 2019 Sep 3. doi: 10.1002/ijc.32663. [Epub ahead of print]

PMID:
31479522
5.

B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.

Nehama D, Di Ianni N, Musio S, Du H, Patané M, Pollo B, Finocchiaro G, Park JJH, Dunn DE, Edwards DS, Damrauer JS, Hudson H, Floyd SR, Ferrone S, Savoldo B, Pellegatta S, Dotti G.

EBioMedicine. 2019 Sep;47:33-43. doi: 10.1016/j.ebiom.2019.08.030. Epub 2019 Aug 26.

6.

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma.

Sun C, Mahendravada A, Ballard B, Kale B, Ramos C, West J, Maguire T, McKay K, Lichtman E, Tuchman S, Dotti G, Savoldo B.

Oncotarget. 2019 Mar 22;10(24):2369-2383. doi: 10.18632/oncotarget.26792. eCollection 2019 Mar 22.

7.

Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies.

Ahn S, Li J, Sun C, Gao K, Hirabayashi K, Li H, Savoldo B, Liu R, Dotti G.

Cancer Immunol Res. 2019 May;7(5):773-783. doi: 10.1158/2326-6066.CIR-18-0636. Epub 2019 Mar 6.

PMID:
30842091
8.

Challenges of driving CD30-directed CAR-T cells to the clinic.

Grover NS, Savoldo B.

BMC Cancer. 2019 Mar 6;19(1):203. doi: 10.1186/s12885-019-5415-9. Review.

9.

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.

Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, Ferrone S, Dotti G.

Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002.

10.

Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.

Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G, Savoldo B.

Clin Cancer Res. 2019 May 1;25(9):2915-2924. doi: 10.1158/1078-0432.CCR-18-1811. Epub 2019 Jan 7.

PMID:
30617136
11.

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.

Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G.

Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.

PMID:
30309819
12.

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.

Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A.

Clin Cancer Res. 2018 Dec 15;24(24):6185-6194. doi: 10.1158/1078-0432.CCR-18-0426. Epub 2018 Aug 10.

PMID:
30097433
13.

CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30- Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions.

Hong LK, Chen Y, Smith CC, Montgomery SA, Vincent BG, Dotti G, Savoldo B.

Cancer Immunol Res. 2018 Oct;6(10):1274-1287. doi: 10.1158/2326-6066.CIR-18-0065. Epub 2018 Aug 7.

14.

Adoptive Cell Therapy in Treating Pediatric Solid Tumors.

Tesfaye M, Savoldo B.

Curr Oncol Rep. 2018 Aug 1;20(9):73. doi: 10.1007/s11912-018-0715-9. Review.

15.

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.

Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2731. doi: 10.1126/scitranslmed.aao2731. Erratum in: Sci Transl Med. 2018 Apr 4;10 (435):.

PMID:
29491184
16.

Treating hematological malignancies with cell therapy: where are we now?

Landoni E, Savoldo B.

Expert Opin Biol Ther. 2018 Jan;18(1):65-75. doi: 10.1080/14712598.2018.1384810. Epub 2017 Oct 5. Review.

PMID:
28978241
17.

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.

Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B.

J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14.

18.

Targeting Immune System Alterations in Hodgkin Lymphoma.

Grover NS, Savoldo B.

Curr Hematol Malig Rep. 2017 Aug;12(4):358-369. doi: 10.1007/s11899-017-0398-6. Review.

PMID:
28780614
19.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K.

Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20.

20.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK.

Mol Ther. 2017 Sep 6;25(9):2214-2224. doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9.

21.

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.

Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, Savoldo B.

Mol Ther. 2017 Mar 1;25(3):580-592. doi: 10.1016/j.ymthe.2017.01.011. Epub 2017 Feb 8.

22.

Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects.

Olive D, Savoldo B, Pastorino F, Castriconi R.

J Immunol Res. 2016;2016:7853028. doi: 10.1155/2016/7853028. Epub 2016 Jun 1. No abstract available.

23.

Glycolysis determines dichotomous regulation of T cell subsets in hypoxia.

Xu Y, Chaudhury A, Zhang M, Savoldo B, Metelitsa LS, Rodgers J, Yustein JT, Neilson JR, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2678-88. doi: 10.1172/JCI85834. Epub 2016 Jun 13.

24.

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.

25.

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Sun C, Dotti G, Savoldo B.

Blood. 2016 Jun 30;127(26):3350-9. doi: 10.1182/blood-2015-12-629089. Epub 2016 May 20. Review.

26.

Chimeric Antigen Receptors for Cancer Immunotherapy.

Geldres C, Savoldo B, Dotti G.

Methods Mol Biol. 2016;1393:75-86. doi: 10.1007/978-1-4939-3338-9_7.

PMID:
27033217
27.

Chimeric antigen receptor-redirected T cells return to the bench.

Geldres C, Savoldo B, Dotti G.

Semin Immunol. 2016 Feb;28(1):3-9. doi: 10.1016/j.smim.2015.12.001. Epub 2016 Jan 12. Review.

28.

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.

Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Strömberg U, Savoldo B, Dotti G, Loskog A.

PLoS One. 2015 Dec 23;10(12):e0144787. doi: 10.1371/journal.pone.0144787. eCollection 2015.

29.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK.

Blood. 2015 Jun 25;125(26):4103-13. doi: 10.1182/blood-2015-02-628354. Epub 2015 May 14.

30.

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA.

Blood. 2015 Jun 18;125(25):3905-16. doi: 10.1182/blood-2015-01-621474. Epub 2015 May 4.

31.

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G.

Nat Med. 2015 May;21(5):524-9. doi: 10.1038/nm.3833. Epub 2015 Apr 13.

32.

K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.

Caruana I, Weber G, Ballard BC, Wood MS, Savoldo B, Dotti G.

Clin Cancer Res. 2015 Jul 1;21(13):2952-62. doi: 10.1158/1078-0432.CCR-14-2998. Epub 2015 Feb 17.

33.

Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.

Perna SK, Huye LE, Savoldo B.

Immunotargets Ther. 2015 Mar 19;4:55-63. doi: 10.2147/ITT.S31389. eCollection 2015. Review.

34.

Survivin-specific T cell receptor targets tumor but not T cells.

Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, Barth P, Dotti G, Savoldo B.

J Clin Invest. 2015 Jan;125(1):157-68. doi: 10.1172/JCI75876. Epub 2014 Nov 21.

35.

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G.

Cancer Res. 2014 Sep 15;74(18):5195-205. doi: 10.1158/0008-5472.CAN-14-0697. Epub 2014 Jul 24.

36.

High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.

Wen J, Li H, Tao W, Savoldo B, Foglesong JA, King LC, Zu Y, Chang CC.

Br J Haematol. 2014 Sep;166(5):711-9. doi: 10.1111/bjh.12951. Epub 2014 May 29.

37.

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G.

Blood. 2014 Jun 12;123(24):3750-9. doi: 10.1182/blood-2014-01-552174. Epub 2014 Apr 29.

38.

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.

Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G.

Blood. 2014 Jun 19;123(25):3895-905. doi: 10.1182/blood-2014-01-551671. Epub 2014 Apr 21.

39.

CD19-CAR trials.

Ramos CA, Savoldo B, Dotti G.

Cancer J. 2014 Mar-Apr;20(2):112-8. doi: 10.1097/PPO.0000000000000031. Review.

40.

Genetic modification of cytotoxic T lymphocytes to express cytokine receptors.

Perna SK, Savoldo B, Dotti G.

Methods Mol Biol. 2014;1139:189-200. doi: 10.1007/978-1-4939-0345-0_17.

PMID:
24619681
41.

Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM.

Clin Cancer Res. 2014 Apr 15;20(8):2215-25. doi: 10.1158/1078-0432.CCR-13-3205. Epub 2014 Feb 26.

42.

Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ.

Cytotherapy. 2014 Jan;16(1):90-100. doi: 10.1016/j.jcyt.2013.07.009. Epub 2013 Oct 26.

43.

T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann M, Ferrone S, Dotti G.

Clin Cancer Res. 2014 Feb 15;20(4):962-71. doi: 10.1158/1078-0432.CCR-13-2218. Epub 2013 Dec 13.

44.

Design and development of therapies using chimeric antigen receptor-expressing T cells.

Dotti G, Gottschalk S, Savoldo B, Brenner MK.

Immunol Rev. 2014 Jan;257(1):107-26. doi: 10.1111/imr.12131. Review.

45.

Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.

Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G.

Clin Cancer Res. 2014 Jan 1;20(1):131-9. doi: 10.1158/1078-0432.CCR-13-1016. Epub 2013 Oct 4. Erratum in: Clin Cancer Res. 2014 Aug 15;20(16):4413.

46.

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment.

Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ.

Cytotherapy. 2014 Jan;16(1):84-9. doi: 10.1016/j.jcyt.2013.07.003. Epub 2013 Oct 1.

47.

Chimeric antigen receptors (CARs) from bench-to-bedside.

Savoldo B, Dotti G.

Immunol Lett. 2013 Sep-Oct;155(1-2):40-2. doi: 10.1016/j.imlet.2013.09.014. Epub 2013 Sep 27. Review.

48.

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G.

Blood. 2013 Oct 24;122(17):2965-73. doi: 10.1182/blood-2013-06-506741. Epub 2013 Sep 12. Erratum in: Blood. 2014 May 22;123(21):3364.

49.

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.

Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, Marcatti M, Saudemont A, Bordignon C, Savoldo B, Ciceri F, Naldini L, Dotti G, Bonini C, Bondanza A.

Blood. 2013 Nov 14;122(20):3461-72. doi: 10.1182/blood-2013-04-493361. Epub 2013 Sep 9.

PMID:
24016461
50.

The immunogenicity of virus-derived 2A sequences in immunocompetent individuals.

Arber C, Abhyankar H, Heslop HE, Brenner MK, Liu H, Dotti G, Savoldo B.

Gene Ther. 2013 Sep;20(9):958-62. doi: 10.1038/gt.2013.25. Epub 2013 May 23.

Supplemental Content

Loading ...
Support Center